Fundraising Fox

Veritas In Silico

Kawasaki, JP · Founded 2016 · 15 employees on LinkedIn · 5 known investors

Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.

AI & Machine LearningBiotechDeep TechMedical Devices

Founders & leadership

SN
Shingo NakamuraCEO

Investors · 5

Global BrainTokyo · $100K – $184M
KDDI Open Innovation Fund
Nippon Venture CapitalTokyo · $1.5M – $269M
Shinsei Capital PartnersTokyo
SMBC Venture CapitalTokyo · $2.3M – $269Mvia Hiroya Ota · inferred

In the news

Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watchedfinance.yahoo.com · Apr 2026Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico - BioSpacebiospace.com · Apr 2026Veritas In Silico Secures European Patent for RNA Discovery | Nasdaqnasdaq.com · Dec 2024Veritas In Silico’s Strategic Shift to Specialty Pharma | Nasdaqnasdaq.com · Dec 2024

Frequently asked questions

What does Veritas In Silico do?
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
Who are Veritas In Silico's investors?
Veritas In Silico's investors include Global Brain, KDDI Open Innovation Fund, Nippon Venture Capital, Shinsei Capital Partners, SMBC Venture Capital.
Where is Veritas In Silico headquartered?
Veritas In Silico is headquartered in Kawasaki, JP.